This trial aims to investigate safety, tolerability, and pharmacokinetics following multiple rising doses of BI 1815368 in healthy male subjects.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
59
BI 1815368
Matching placebo
SGS Life Science Services - Clinical Research
Edegem, Belgium
Percentage of patients treated who experience treatment-emergent adverse event assessed as drug-related by the investigator
Time frame: Up to 29 days
Area under the concentration-time curve of BI 1815368 in plasma at steady state over a uniform dosing interval τ (AUCτ,ss)
Time frame: Up to 16 days
Minimum concentration of BI 1815368 in plasma at steady state over a uniform dosing interval τ (Cmin,ss)
Time frame: Up to 16 days
Maximum measured concentration of BI 1815368 in plasma at steady state over a uniform dosing interval τ (Cmax,ss)
Time frame: Up to 16 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.